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Introduction
For many years, mushrooms have been used for treating various
health conditions or diseases due to their therapeutic properties.
The practice of using mushrooms is common in traditional medicine
but has also recently attracted increased attention in conventional
medicine. With the rise of mushroom-based drugs in the pharmaceutical
industry, their therapeutic potential is well established (1,2).
Extracted compounds from mushrooms of the genus Ganoderma
exhibit potential medicinal effects in the treatment of various human
diseases (3), particularly cytotoxicity (4), antimicrobial (4), antioxidant
(5), immunomodulatory (5), and antifungal (6) properties,
demelanization (7), and nitric oxide (NO) production (8).
Ganoderma lucidum is a well-known species of mushroom, and its
use in traditional medicine has prompted scientists worldwide to
undertake mass cultivation and production of the bioactive
metabolites of this fungus (9-11). It produces several functional
metabolites with biological activity, such as polysaccharides (4),
proteins (6), and ganoderic acids (12), which might explain some of
the observed medicinal properties. The polysaccharide fractions
appear to be the primary source of the biological activity of G.
lucidum (13). The solubility of these polysaccharides has been
improved to widen their application and ease of experimental use
(14), resulting in highly bioactive sulfated polysaccharides (4).
Sulfated polysaccharides or glucans are commonly found in
marine organisms (15) and have recently been reported as less
prevalent in mushrooms (4). However, the sulfated glucan with a
proposed structure of β-1,3-D-glucan, derived from the mycelium of
the mushroom G. lucidum, has exhibited antimicrobial activity
against normal pathogenic bacteria. It has also been shown to be
noncytotoxic to normal human cells. This glucan sulfate (GS) is
soluble and its therapeutic activities is significantly impactive
compared with nonsulfated glucans (4). Based on this properties, G.
lucidum glucan compounds (16) could be utilized for their
prospective bifunctional effects (17).
G. lucidum has been shown to possess various biological activities
including a demelanizing effect and antifungal activity (6,18). A great
deal of interest has also focused on the immunomodulatory ability of
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Abstract Underutilized mycelium of Ganoderma lucidum BCCM 31549 has been a significant source
of a glucan sulfate (GS) possessing therapeutic activities. GS have been evaluated for their antifungal-
demelanizing properties and nitrite oxide production from stimulated RAW264.7 macrophages. GS
exhibited antifungal activity against Aspergillus niger A60 with a minimum inhibitory concentration of
60 mg/mL and a minimum fungicidal concentration of 100 mg/mL. At 60 mg/mL (sublethal) and
30 mg/mL (subinhibitory) doses of GS, the mycelium of A. niger A60 was successfully demelanized with
a conidiophore head and black pigment reduction. Additionally, GS successfully stimulated RAW264.7
macrophage cells at a concentration of 500 μg/mL to produce 0.45 μM of nitric oxide. The GS-
stimulated RAW264.7 macrophages were morphologically similar to those treated with lipopolysaccharide.
The results highlight a novel bifunctional property of mycelial GS from G. lucidum.
Keywords: antifungal activity, demelanization, Ganoderma lucidum, glucan sulfate, nitric oxide production
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this species pertaining to macrophages (white blood cells).
Macrophages act as the major host barrier against cancer growth
and bacterial infection (19,20), and consequently, play an imperative
function as an initiator for adaptive immune responses caused by
NO.
A highly-reactive free radical compound, NO is produced by NO
synthase from L-arginine (21). It causes cytolysis in tumors and is
therefore implicated in the antitumor immune response (19).
Activated macrophages release NO (8), which provides a defense
mechanism against pathogens by modulating inflammation.
However, most of the reported positive bioactivities mentioned
above were demonstrated in compounds obtained from fruiting
bodies and not from their mycelial cultures in bioreactors. Such
cultures represent a faster way to produce bioactive compounds
from G. lucidum compared with extraction from mushrooms, as
discussed in a previous study (9). The current study examines the
biological activity of β-glucan produced from mycelial cultures.
To date, NO production activity and the antifungal-demelanizing
properties of G. lucidum mycelial extracts, mostly GS, have not been
evaluated. In this study, GS showed significant antifungal-demelanizing
activity in addition to activating RAW264.7 macrophage cells, and
hence could potentially be utilized as a food additive. In doing so, its
presence would inhibit both pathogenic and spoilage fungi while
conveying the important health benefits described in this study.
Materials and Methods
Materials The RAW264.7 mouse macrophage cell line was
obtained from the European Collection of Authenticated Cell
Cultures (ECACC), in partnership with Sigma-Aldrich (St. Louis, MO,
USA). Roswell Park Memorial Institute (RPMI) medium containing
10% fetal bovine serum, 100 μg/mL streptomycin, and 100 U/mL
penicillin (Sigma-Aldrich) was used to culture the cell line in a 5% CO2
atmosphere at 37oC. RPMI-Bio Whittaker® (lacking L-glutamine) was
obtained from Lonza (Vergiers, Belgium). Hank’s balanced salt
solution (HBBS) was obtained from Sigma-Aldrich. For cell culture,
96-well plates (TPP 92096) were obtained from TPP (Trasadingen,
Switzerland). A standard Wallac Victor2TM H20 (PerkinElmer, Waltham,
MA, USA) multilabel counter with infrared, high-density time-
resolved (TR)-fluorometry, robot loading and stacker was used for
cell culture spectroscopy analysis. All chemicals and solvents used for
analysis were of analytical grade. Aspergillus niger A60 was obtained
from the Fermentation Centre, Strathclyde Institute of Pharmacy and
Biomedical Sciences (SIPBS), University of Strathclyde, Glasgow, UK
and used for the screening study. Potato dextrose agar (PDA) was
used for culture maintenance at 4oC. Only cultures from the
standardized stock culture stored in a −80oC freezer were used.
Source of sulfated glucan G. lucidum BCCM 31549 was obtained
from the Belgian Coordinated Collections of Microorganisms (BCCM/
MUCL), (Agro) Industrial Fungi and Yeast Collection (Leuven,
Belgium) and subcultured onto PDA (Oxoid Limited, Basingstoke,
UK). Plates were inoculated and incubated at 30oC for 7 days prior to
storage at 4oC. Strain preservation was performed on PDA slants. The
liquid fermentation strategy was implemented in a 2.5 L stirred-tank
bioreactor (Bioflow 3000 Fermentor; New Brunswick, Ramsey, MN,
USA) as described previously (9), and the mycelium was extracted to
produce glucan. The sulfated (1,3)-β-D-glucan (4) was obtained from
the sulfation process of the native glucan and used in the screening
study.
Bioassay for antifungal and demelanizing activity on A. niger A60
A modified microdilution technique from Heleno et al. (7) was used
to examine the antifungal activity of GS in terms of measuring the
minimum inhibitory concentration (MIC) and minimum fungicidal
concentration (MFC). GS was dissolved in 5% DMSO solution
containing 0.1% Tween 80 (v/v) at (mg/mL): 200, 125, 100, 60, 30,
20, 15, 10, 2, and 1 and added to potato-dextrose medium with
inoculum. A commercial fungicide, bifonazole (Sigma-Aldrich), was
used as a positive control (2 mg/mL) with DMSO as a negative
control.
The demelanizing activity of GS on A. niger A60 was tested in 96-
well microtiter plates in order to determine the minimum
demelanizing concentration (MDC) (7). Examination of the treated
mycelium after fixation with lactophenol was accomplished using a
light microscope (Nikon, Tokyo, Japan). The untreated control plate
samples were also examined under the same conditions. DMSO (5%)
solution was used as a negative control. The MDC was defined as the
lowest concentration that caused the demelanization of conidia and
fungal hyphae.
Stimulation of macrophage cells and measurement of NO
RAW264.7 macrophages were cultivated according to the technique
of Chiong et al. (20), with some modifications. Following centrifugation
at 112xg and 4oC, cell density was adjusted to 2.5–3×105 cells/mL.
Cell viability was maintained at above 80%. Seventy-five µL of cells
were dispensed into each well of the 96-well plates to obtain 5×104
cells/well. Plates were incubated for 6 h at 37oC in a 5% CO2
atmosphere to attach the cells. Floating cells were discarded gently
after 2 h of incubation while attached cells were removed mechanically
(Corning® cell scraper, Sigma-Aldrich) to collect the desired cell
population. The concentrations of glucan, GS, and 0.1 M NaOH
(solvent and negative control) used to stimulate the attached cells
were (μg/mL) 500, 200, and 50, in a final volume of 200 μL/well. As a
positive control, lipopolysaccharide (LPS) extracted from Escherichia
coli 0111: B4 (Sigma-Aldrich) was used. Incubation for 24 h at 37oC in
a humidified 5% CO2 atmosphere was standard for all cell cultures.
The level of NO in cell-free culture supernatants, which reflects
intracellular NO synthase activity, was evaluated by the Griess
reaction using a colorimetric nitrate/nitrite assay kit (23479; Sigma-
Aldrich). Assay sample preparation was performed by centrifuging
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the reacted medium at 150xg for 15 min, and supernatant was used
as a sample solution. The determination of nitrite was performed in
96-well plates. Sample solutions (80 μL) were added to each well,
followed by 20 μL of buffer solution. Next, 80 μL of Griess Reagent A
was added and mixed. After 5 min, 50 μL of Griess Reagent B was
added and mixed. Plate incubation was performed at room temperature
and absorbance was measured at 570 nm in a microplate reader. For
the calculation of NO levels, the blank solution (well A) absorbance
was subtracted from the absorbance of each well. Nitrite concentration
in the sample solution was determined from a predetermined nitrite
standard calibration curve. 
Statistical analysis Analyses were carried out in triplicate, and the
respective mean±SD was calculated using GraphPad Prism 5
software (Version 5.01). Error bars were shown accordingly, and if
not visible, were less than the size of symbols used. Statistical
differences were determined using Student’s t-test, one-way analysis
of variance (ANOVA), and Bonferroni’s post-test.
Results and Discussion
Antifungal activity of GS on A. niger A60 The antifungal activity of
GS against A. niger A60 is shown in Table 1 with the growth
morphology (elongated fungal mycelial filaments) shown in Fig. 1. GS
exhibited antifungal activity against the test fungi with an MIC of 60
mg/mL and MFC of 100 mg/mL. In this study, antifungal screening
was performed on A. niger A60 as previous work on an extract from
G. lucidum fruiting bodies showed that it had the highest antifungal
activity against this fungus (7). Our data showed that the GS derived
from G. lucidum mycelia inhibited the growth of A. niger. However,
only nonsulfated compounds present in Ganoderma species have
been reported as antifungal, including three triterpenes (applanoxidic
acids A, C, and F) produced by G. annulare sourced from decayed
wood (22), the fruiting bodies extract of G. lucidum (7), and
Ganodermin sourced from G. lucidum fruiting bodies (6). Few studies
have been reported on the antifungal activity of nonsynthetic
polysaccharides containing sulfate residues that are mostly in
synthetic forms (23). To the best of our knowledge, our study is the
first report of the antifungal activity of any possible sulfated
polysaccharides derived from G. lucidum mycelium via extended
batch cultures (4,9).
Demelanizing effect of GS on A. niger A60 The demelanizing
activity of GS was investigated in A. niger A60. The results were
expressed in terms of the MDC, which was defined as the subinhibitory
and sublethal concentrations that caused demelanization in the
fungus during a 72 h. The subinhibitory level was 30 mg/mL,
whereas the sublethal concentration was 60 mg/mL of GS (Fig. 2,
images A-F).
The morphological changes that occur during the melanization of
A. niger can be observed in Fig. 2 and represent depigmentation.
Table 1. Antifungal activity, minimum inhibitory concentration (MIC),
and minimum inhibitory concentration (MFC) of glucan sulfate (GS)
(mg/mL) derived from extended batch cultures of Ganoderma lucidum
BCCM 31549 mycelium
Fungus




Aspergillus niger A60 60 100 (+) control (-) control
Fig. 1. Growth morphology of A. niger A60. (A) Positive control reaction with bifonazole at 2 mg/mL; (B) Negative control reaction with 5% DMSO
solution; (C-F) Positive antifungal treatment reactions with glucan sulfate derived from extended batch cultures of G. lucidum BCCM 31549
mycelium at (C) 200, (D) 100, (E) 60, and (F) 30 mg/mL. Images were taken at 4-fold magnification using a compound microscope. Bar=150 µm.
*Heavier filament growth indicates lower antifungal activity.
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Upon observing the morphological variations of the conidiophores, it
was noted that demelanized cultures of the tested fungi displayed a
markedly reduced number of heads (Fig. 2A and 2B) in comparison
with those in the untreated culture (Fig. 2C). The reduction of heads
and demelanization of A. niger A60 spores were also observed under
a light microscope (Fig. 2D and 2E) and compared with an untreated
control (Fig. 2F). Melanin plays a vital role in fungal virulence and has
been described as “fungal armour” due to its ability to shield against
a broad range of toxins (24). It may also play a role in the survival of
fungi in extreme environments (25). Therefore, disrupting the fungal
armour (demelanization) would suppress the growth of pathogenic
fungi such as A. niger. 
Melanin has also been shown to protect the fungus against
immune effector cells as it scavenges reactive oxygen species produced
by these cells (26). The GS of G. lucidum showed a subinhibitory and
sublethal MDC as mentioned in the text; thus we believe that the GS
is directly involved in the modification or inhibition of the
demelanization mechanism. Demelanizing activity outcomes are
vital for the present work, since MDC is sublethal to fungus in
contrast to the inhibitory and fungicidal doses.
Comparison with antifungal reactions of compounds extracted
from G. lucidum The use of GS as an antifungal compound has not
been reported previously (Table 2); therefore, the comparison of
antifungal reactions is limited to available research that utilized any
G. lucidum constituents extracted from mycelium or fruiting bodies.
When compared with previous A. niger antifungal work by Heleno
(7), the current values for MIC, MFC, and MDC (Table 1 and Fig. 2)
were higher with the same pigmentation, shape, and size when
viewed under the microscope. However, Fagade and Oyelade (27)
tested G. lucidum extracts on several microorganisms and found that
the MIC of Candida albicans was 750 mg/mL, which is higher than
the MIC (60 mg/mL) we observed on A. niger A60. Higher MIC
means that the extract is less potent, so this may indicate that the
current extracted compound is more suitable for treating
Aspergillosis (caused by A. niger) than Candidiasis (caused by C.
albicans). Further studies are needed to confirm this, however.
Nevertheless, when compared with an earlier medicinal
Table 2. Antifungal activity of active constituents from Ganoderma lucidum
Source Compound Tested fungus MIC2) (mg/mL) Reference
Mycelium Glucan sulfate Aspergillus niger A60 60 This study
Fruiting bodies Methanol extract A. niger 1.5 (7)
NA1) Ganozhi toothphase, DXN Industries (M) Sdn. Bhd. Malaysia C. albicans 2 (18)
Fruiting bodies Ethanolic extract C. albicans 750 (27)
Fruiting bodies Ganodermin (peptides) Botrytis cinerea NA (6)
1)NA, Not available. The comparison is based on the available literature for G. lucidum.
2)MIC=minimum inhibitory concentration.
Fig. 2. Effect of glucan sulfate (GS) on antifungal-demelanizing properties of A. niger A60. (A) Demelanized mycelium of A. niger A60 stimulated
with GS at 60 mg/mL; (B) Demelanized mycelium of A. niger A60 stimulated with GS at 32.5 mg/mL; (C) Normal mycelium of A. niger A60 without
stimulation; (D) Culture of A. niger A60 with fewer heads, stimulated with GS at 65 mg/mL; (E) Culture of A. niger A60 with fewer heads, stimulated
with GS at 30 mg/mL; and (F) Typical culture of A. niger A60 with numerous heads. (D-F) Images were obtained under light microscopy. GS was
derived from extended batch cultures of G. lucidum BCCM 31549 mycelium. *Black conidiophores indicate weaker demelanizing reactions.
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application of antifungal toothpaste containing G. lucidum against C.
albicans at sensitivity concentrations of (mg/mL): 500, 250, 125,
62.5, 31.25, 16, 8, 4, and 2 (18), the current tested concentrations
(mg/mL: 200, 125, 100, 60, 30, 20, 15, 10, 2, and 1) are
approximately similar, thus indicating the suitability of G. lucidum
extracts for future use in the bioproducts industry. To the best of our
knowledge, the current G. lucidum BCCM 31549 mycelium extract
derived from repeated-batch cultures (4,9,10) is the latest compound
shown to possess antifungal-demelanizing activity against A. niger
A60. Further modifications of this compound, including purification
and fractionation, and further testing of its applicability as a food
additive and in clinical and animal studies would be beneficial.
Effect of GS on NO production in macrophages As shown in Fig. 3,
our study shows that NO production from RAW264.7 cells stimulated
with GS (500, 200, and 50 μg/mL) for 48 h increased significantly
compared with untreated controls. GS was more effective than the
native glucan in initiating the release of NO from the macrophages,
with 0.45, 0.29, and 0.18 μM of NO released and 0.08, 0.035, and
0.013 μM of NO released, respectively, at concentrations of 500, 200
and 50 μg/mL of GS and glucan. In human health systems, sustained
production of NO confers macrophages with cytotoxicity against
fungi, protozoa, viruses, bacteria and tumor cells (28). GS may
therefore contribute to the high-output NO pathway in order to
protect the host from infection.
Furthermore, no macrophage reactions were observed with 0.1 M
NaOH, the solvent used for both glucan and GS (no pseudopodia
were observed), indicating that the NO increase originated solely
from to the compounds themselves (Fig. 4). Meanwhile, the
stimulated-macrophage morphological reactions showed that the
GS-stimulated macrophage was morphologically similar to 2 μg/mL
of LPS at concentrations of 500 and 200 μg/mL. Darker green
macrophages were associated with a change in macrophage
morphology, causing them to take on a fibroblast-like appearance
(29) or pseudopodia formation (21). Meanwhile, glucan-stimulated
macrophages showed minimal morphological responses while the
solvent proved to be unreactive towards the macrophage cells.
A polysaccharide isolated from G. lucidum fruiting body has
already been shown to stimulate the release of NO (19). However,
Fig. 3. Effect of glucan (G) and glucan sulfate (GS) on NO production by
RAW264.7 macrophages. Cells were treated with different
concentrations of compounds or LPS (2 µg/mL) for 48 h and culture
supernatants were analyzed for NO production. Each value is the
mean±SD of two independent experiments, performed in triplicate.
**p<0.05, significant difference from the control group.
Fig. 4. Reaction diagram of NO production by RAW264.7 macrophages stimulated with glucan (G) and glucan sulfate (GS). NaOH (0.1M) was used
as the solvent (indicating a negative reaction) for both compounds indicating a positive reaction independently from G and GS. All images were at
10x magnification. *Darker green indicates greater NO production.
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the effect of liquid-mycelial GS has not yet been reported. The
current study is the first to utilized a sulfated polysaccharide
obtained from G. lucidum mycelium that possesses immuno-
modulatory reactions. The level of NO secreted from RAW264.7 cells
in the presence of the glucan was observed to be very low (<0.1 μM),
indicating its weak ability to trigger macrophages compared with GS.
GS was less potent than the LPS positive control; however, the results
are similar to those previously achieved using the aforementioned
polysaccharide purified from G. lucidum fruiting bodies (19) and has
been described as a safe compound in human cell lines (4),
suggesting that GS has potential as an immunomodulator. 
The GS results are comparable with those of non-sulfated
polysaccharides from the mycelia of G. lucidum (30). That study
reported stimulated growth of macrophage cells and higher levels of
NO (16–17 μM at 40 μg/mL of polysaccharides) than the compounds
evaluated in previous studies. It is possible that this observation
was due to differences in the structure and composition of the
polysaccharides when the fungus was grown in different media. The
nonsulfated polysaccharides of G. lucidum were obtained via solid-
state fermentation using soybean curd residue (31), whereas glucan
was obtained through a newly implemented repeated-batch strategy
with subsequent sulfation to yield GS (4,9). Further experiments
comparing the polysaccharides produced through different culture
methods should be performed to determine the optimum mono-
saccharide composition and, subsequently, the optimum culture
method for the production of macrophage-stimulating polysaccharides.
In summary, GS extracted from G. lucidum BCCM 31549 mycelium
not only has strong antimicrobial activity and considerable
cytotoxicity against cancer cells (4), but also exhibits substantial
antifungal-demelanizing and immunomodulatory activity. It therefore
shows potential as a solution to the current research interest in
producing drugs with antibacterial, anticancer, or antifungal activity
as well as immunomodulating properties (32).
Relationship between antimicrobial, cytotoxicity, antifungal
properties and immunomodulation by GS Despite recent
advances in the treatment of infections, the issue of drug resistance
persists (33). Each year, approximately 15 million people die from
contagious infections (34). With the improvement of microorganism
survival rate, more research must be dedicated to the development
of host immunomodulatory and antimicrobial-synergistic drugs to
effectively battle new types of infections. Various drugs are already
available on the market that can be prescribed in combination with
antifungal or antibacterial agents.
We are now in the third generation of the anti-infective plan (17),
which centers on the chemistry between antibiotics and host
immunomodulation. Our previous (4) and current results have
indicated the potential of the aforesaid anti-infective plan, starting
with antibacterial, antifungal, immunomodulatory, and antiproliferative
compounds, thus introducing a novel “quad-functional” approach to
the nutraceutical potential of the mushroom species, mainly through
the G. lucidum mycelia-sourced polysaccharides. To date, the closest
comparison to the current G. lucidum reaction is found in the hot-
water mycelial extract of the oyster mushroom, exhibiting
“bifunctional” properties (antimicrobial-immunomodulatory) (17).
To date, approximately 83% of all edible-medicinal mushroom
products are obtained from fruiting bodies, while 15% are obtained
from the mycelial extracts (35). This research indicates that G.
lucidum mycelia may also represent an easily accessible and
renewable resource compared with fruiting bodies for producing
anti-infective agents.
The sulfated glucan extracted from the mycelium of G. lucidum
BCCM 31549 showed antifungal-demelanizing activity in A. niger A60
and successfully stimulated RAW264.7 macrophage cells to produce
an important mediator, NO. Our findings therefore demonstrate the
possible applications of GS as a pharmacological, medicinal, and
functional food ingredient with multifunctional benefits (antifungal
and immune-stimulatory). Further studies are required, however, to
elucidate the relationship between its molecular structure and
biological activities.
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